99mTc-MIBI Lung Scintigraphy in the Assessment of

Pulmonary Involvement in Interstitial Lung Disease and Its

Comparison With Pulmonary Function Tests and

High-Resolution Computed Tomography by Assadi, Majid et al.
icine®
ONAL STUDYMed
OBSERVATI99mTc-MIBI Lung Scintigraphy in the Assessment of
Pulmonary Involvement in Interstitial Lung Disease and Its
Comparison With Pulmonary Function Tests and
High-Resolution Computed Tomography
A Preliminary StudyMMehrzad Bahtouee, MD, Jamshid Saberifard,
M
alive over the 1-year follow-up period. There was also a significant
difference between the uptake intensity of 99mTc-MIBI and the
outcome in the early phase (dead: 0.32[0.29–0.43] vs alive:
the qualitative interpre
which are well correla
the most simple modal
Editor: Gaurav Malhotra.
Received: June 25, 2015; revised: September 30, 2015; accepted: October
24, 2015.
From the Department of Internal Medicine (Division of Pulmonary),
Bushehr Medical Center Hospital (MB); Department of Radiology,
Bushehr Medical Center Hospital, Bushehr University of Medical Sciences,
Bushehr (JS); Golestan Research Center of Gastroenterology and
Hepatology (GRCGH), Golestan University of Medical Sciences
(GUOMS), Gorgan (HJ); The Persian Gulf Tropical Medicine Research
Center, (IN, AR); The Persian Gulf Nuclear Medicine Research Center,
Bushehr University of Medical Sciences, Bushehr (MA); and Research
Center for Nuclear Medicine, Tehran University of Medical Sciences,
Tehran, Iran (ME).
Correspondence: Majid Assadi, The Persian Gulf Nuclear Medicine
Research Center, Bushehr University of Medical Sciences, Bushehr
3631, Iran (e-mail: assadipoya@yahoo.com, asadi@bpums.ac.ir).
The authors have no conflicts of interest to disclose.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
This is an open access article distributed under the Creative Commons
Attribution License 4.0, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
ISSN: 0025-7974
DOI: 10.1097/MD.0000000000002082
Medicine  Volume 94, Number 47, November 2015MD, Iraj Nabi
Alireza Raeisi, MD, Majid Assadi,
Abstract: The differentiation of active inflammatory processes from
an inactive form of the disease is of great value in the management of
interstitial lung disease (ILD). The aim of this investigation was to
assess the efficacy of 99mTc-methoxy-isobutyl-isonitrile (99mTc-
MIBI) scans in distinguishing the severity of the disease compared
to radiological and clinical parameters.
In total, 19 known cases of ILD were included in this study and were
followed up for 1 year. Five patients without lung disease were
considered as the control group. The patients underwent pulmonary
function tests (PFTs) and high-resolution computed tomography scans,
followed by 99mTc-MIBI scanning. The 99mTc-MIBI scans were
analyzed either qualitatively (subjectively) or semiquantitatively.
All 19 ILD patients demonstrated a strong increase in 99mTc-MIBI
uptake in the lungs compared to the control group. The 99mTc-MIBI
scan scores were higher in the patient group in both the early phase
(0.24[0.19–0.31] vs 0.11[0.10–0.15], P< 0.05) and the delayed phase
(0.15[0.09–0.27] vs 0.04[0.01–0.09], P< 0.05) compared with the
control group. A positive correlation was detected between the
99mTc-MIBI scan and the high-resolution computed tomography
(HRCT) scores (Spearman’s correlation coefficient ¼ 0.65, P< 0.02)
in the early phase but not in the delayed phase in patients (P> 0.14). The
99mTc-MIBI scan scores were not significantly correlated with the PFT
findings (P> 0.05). In total, 5 patients died and 14 patients were stillD, Hamid Javadi, pour, MD,
D, and Mohammad Eftekhari, MD
0.21[0.18–0.24], P< 0.05) and delayed phase (dead: 0.27[0.22–0.28]
vs alive: 0.10[0.07–0.19], P< 0.05).
The washout rate was 40 min starting from 20 min up to 60 min
and this rate was significantly different in our 2 study groups (ILD:
46.61[15.61–50.39] vs NL: 70.91[27.09–116.36], P¼ 0.04).
The present study demonstrated that 99mTc-MIBI lung scans might
distinguish the severity of pulmonary involvement in early views, which
were well correlated with HRCT findings. These results also revealed
that 99mTc-MIBI lung scans might be used as a complement to other
diagnostic and clinical examinations in terms of functional information
in ILD; however, further investigations are strongly required.
(Medicine 94(47):e2082)
Abbreviations: 99mTc-DTPA = 99mTc-diethylene triamine
pentaacetic acid, 99mTc-MIBI = 99mTc-methoxy-isobutyl-
isonitrile, CTD = connective tissue disease, FEV1 = forced
expiratory volume in the first second, FVC = forced vital
capacity, HRCT = high-resolution computed tomography, ILD =
interstitial lung disease, PFT = pulmonary function test, ROI =
region-of-interest, SPECT = single-photon emission computed
tomography, WR = washout rate.
INTRODUCTION
I nterstitial lung disease (ILD) and diffuse parenchymal lungdisease are characterized by inflammation and fibrosis in the
alveoli, distal airways, and septal interstitium of the lungs.1–3
Timely and precise identification of ILD can be challen-
ging, but it is critical to the patient’s management.4,5 Generally,
the clinical impression is based on the integration of clinical,
radiological, and histopathological features.6
Interstitial lung disease identification is ultimately
launched by a lung biopsy, which is an invasive method, and
is problematic to repeat during follow-up. Moreover, histologi-
cal findings are not absolutely in accordance with the clinical
severity of the disease.7 In most clinical scenarios no single
investigation modality is perfect. Ideally a combination of
modalities may be required to ascertain the best judgment.
Currently, high-resolution computed tomography (HRCT)
and pulmonary function tests (PFTs) are the most commonly
used noninvasive diagnostic tests for the assessment of ILD.8
Although the findings from the HRCT are related to the
histological findings, its clinical effectiveness is hampered bytation of the results.9 Furthermore, PFTs,
ted to a biopsy and HRCT findings, are
ity for follow-up studies.10 Nonetheless,
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their clinical value is debatable, especially when there are
contradictory findings from the PFTs and HRCT.11 Hence,
the ideal approach to judge pulmonary involvement in patients
with ILD remains uncertain.
In nuclear medicine fields, 67Ga-citrate, 111In-octreotide,
and 99mTc-diethylene triamine pentaacetic acid (99mTc-
DTPA) aerosol for scintigraphic recognition of ILD have been
proposed.4,12–14 However, an optimal modality with a high
concordance with HRCT and PFT findings is still missing.
One lipophilic imaging agent that is widely applied for the
diagnosis of coronary artery disease by scintigraphy is 99mTc-
labeled methoxy-isobutyl-isonitrile (MIBI).15 This agent can
attach to an unidentified cytosolic protein, or become seques-
tered in mitochondria.16 In vivo, 99mTc-MIBI is picked up by
tissues containing a lot of mitochondria, such as cardiac muscle
and tumors.17 In vitro, 99mTc-MIBI accumulates in cultured
myocytes, endothelial cells, and in v-src-transformed, but not in
untransformed, NIH 3T3 fibroblasts.18
Abnormal activity of 99mTc-MIBI by neoplastic tissues in
the lungs has been mentioned previously, but pulmonary uptake
in non-neoplastic conditions seems to be extremely infre-
quent.19
Although reports from preclinical and pilot studies are
promising, this agent is not presently applied for routine clinical
use. We aimed to ascertain the efficacy of 99mTc-MIBI lung
scans in the early detection and evaluation of the severity of
pulmonary involvement in patients with ILD.
MATERIALS AND METHODS
Participants
This study was conducted on 19 patients with a history of
ILDwhowere referred from the lung department of a university
hospital to our research center. Participants excluded from this
study included those with a history of chronic respiratory
disease, chronic cardiac failure, lung cancer, severe pulmonary
arterial hypertension, and a recent history or signs of respir-
atory infection at the time of the study. Also excluded were
those with an Ig-A deficiency, heavy smoking, and a history of
immune-mediated reactions to blood transfusions. The patients
underwent PFTs and HRCT scans followed by 99mTc-MIBI
scanning. They were then followed for 1 year. Corticosteroids
were not used before scanning. Five patients without lung
disease, who were assessed with 99mTc-MIBI scintigraphy
for the diagnostic workup of myocardial perfusion, were
considered as the control group for 99mTc-MIBI uptake in
the lungs.
This study complies with the Declaration of Helsinki and
was approved by the Institutional Ethics Committee of Bushehr
University of Medical Science. All patients provided their
written informed consent prior to the study.
Severity Grading of Respiratory Complications
Pulmonary function parameters were acquired with a
spirometer (ZAN 100, Me, grera¨te GmbH, Germany). The
severity grading of respiratory damage was categorized based
on the patient’s forced vital capacity (FVC) and forced expira-
tory volume in the first second (FEV1). Normal respiratory
function (grade 1) was described as an FVC  80% and an
FEV1  80% of the predicted value. Mild respiratory damage
Bahtouee et al(grade 2) was described as an FVC¼ 60% to 79% or an
FEV1¼ 60% to 79% of predicted values; moderate (grade 3)
was an FVC¼ 50% to 59% or an FEV1¼ 40% to 59% of
2 | www.md-journal.compredicted values; and severe (grade 4) was an FVC< 50% or an
FEV1< 40% of predicted values.20
High-Resolution Computed Tomography Scan
High-resolution computed tomography images were per-
formed on an electron beam CT machine. All 1.5mm sections
were done at full inspiration both in the supine and prone
positions. In all participants, additional expiratory films and
prone sections were acquired. Images were photographed at
window settings proper for inspecting the lung parenchyma.
The scans, together with plain chest radiographs, were assessed
by a pulmonary radiologist. The possible patchy ground glass
pattern, reticular pattern, emphysema, honeycombing, airway
distortion, and bronchial wall thickening appearances were
recorded. The parenchymal patterns identified on HRCT were
coded, and a score was delineated according to Goldin et al.21
For the appraisal of severity, a point value was allocated to each
pattern as follows: pure ground-glass opacity, fibrosis (includ-
ing thickened reticular markings, bronchiectasis, and bronch-
iolectasis), and honeycombing.21
An ‘‘extent of disease’’ score was attained by the percen-
tage of disease extent for each appearance: normal was scored
as a 0 with all others scored as follows: 1< 25%; 2¼ 25% to
50%; 3¼ 50% to 75%; and 4> 75%. Three zones were con-
templated as follows: zone 1, apex to aortic arch; zone 2, aortic
arch to inferior pulmonary veins; and zone 3, inferior pulmon-
ary veins to the diaphragm. The right and left lungs were scored
separately.21 Lastly, the scores for the severity and extent of the
disease were added to acquire a total HRCT score. For example,
a participant with a ground-glass appearance in >75% of 6
zones in both lungs was scored with this equation: 6  4¼ 24
score. Honeycombing in <25% of 3 zones in the right lung and
also<25% of zone 1 in the left lung, in 50% to 75% of zone 2 of
the left lung, and in 24% to 50% of zone 3 of the left lung but
lack of reticular fibrosis in any part of the lung would have a
total HRCT score of 33.21
Imaging Protocols
99mTc-MIBI Scintigraphy
Scans were performed with commercially available MIBI
kits that were prepared using freshly eluted 99mTc and the
labeling efficiency of MIBI was always >95%.
The 99mTc-MIBI imaging was performed using a large
field of view gamma camera fitted with a low-energy, all-
purpose collimator. Anterior and posterior images of the chest
were obtained 20 min and 60 min following the intravenous
injection of 370 MBq (10 mCi) 99mTc-MIBI. Images were
obtained using a double detector system (ADAC Genesys
Malpitas, CA) with a low-energy, all purpose (LEAP) collima-
tor. For 99mTc-MIBI single-photon emission computed tom-
ography (SPECT), a symmetric 15% window was centered at
140KeV. Images were recorded in a 256 256 wordmatrix on a
nuclear medicine computer. To reduce the superimposed scap-
ular and pectoral muscular activities from the field of the lungs,
acquisition was performed in the hands-overhead position. In
instances of no abnormality on the early images, either
additional oblique-lateral views or SPECT images were taken
following late planar imaging to enhance lesion detectability.
The 99mTc-MIBI scintigraphy assessment of MIBI uptake was
Medicine  Volume 94, Number 47, November 2015done qualitatively (subjectively) and quantitatively. A nuclear
medicine specialist evaluated the projections to optimize the
quality of the images.
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Image Analysis
Images were assessed by 2 nuclear medicine physicians
who were blinded to all other clinical and imaging information.
The interobserver variability was resolved by a consensus.
Patients showing an increased uptake in early or delayed
images, or both images, were regarded as positive. The radio-
nuclide uptake was characterized as follows: no uptake (),
mild uptake (), moderate uptake (þ), and severe uptake (þþ).
For semiquantitative interpretation, a region-of-interest
(ROI) analysis was carried out on the anterior and posterior
views of the lungs and also a region on the deltoid muscle. The
mean count per pixel of the same size of upper, middle, and
lower regions of each lung, and the heart were subtracted from
the deltoid region yielding net counts per pixel. The geometric
mean of these ROIs was determined. The ratio of the mean
counts of these ROIs and the counts of the ROI over the heart
divided by 2 gave a value for each patient that represented the
disease severity using 99mTc-MIBI scintigraphy (MIBI score).
Statistical Analysis
A 2-tailed t test was used to compare the mean values
between groups. The continuous variables are expressed as the
mean standard deviation (SD), and categorical variables as
the absolute values and percentages. The distribution of the
variables was assessed using probability plots and the Shapiro-
Wilk test and they were not fit to a Gaussian distribution. The
Mann–WhitneyU test was applied for quantitative comparisons
of MIBI scores between the patient and control groups. The
Spearman rank test was used for correlations. A P value
Medicine  Volume 94, Number 47, November 2015of< 0.05 was considered statistically significant. Statistical
analysis was performed using an IBM computer and PASW
software, version 18.0 (SPSS, Inc, Chicago).
TABLE 1. The Comparison of 99mTc-MIBI Scintigraphy Scores Be
MIBI Scintigraphy Score Early Phase

Upper right lung Case 0.18(0.13–0.26)
Control 0.10(0.10–0.11)
Middle right lung Case 0.29(0.20–0.34)
Control 0.14(0.11–0.17)
Lower right lung Case 0.31(0.28–0.42)
Control 0.13(0.10–0.23)
Upper left lung Case 0.18(0.10–0.24)
Control 0.08(0.07–0.10)
Middle left lung Case 0.22(0.17–0.30)
Control 0.12(0.10–0.13)
Lower left lung Case 0.27(0.21–0.33)
Control 0.13(0.10–0.20)
Total lung Case 0.24(0.19–0.30)
Control 0.11(0.10–0.15)
All values are significant. 99mTc-MIBI¼ 99mTc-methoxy-isobutyl-ison
Median, interquartile range.
yMann–Whitney test.
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This study included 10 males and 9 females (mean age:
49.33 5.42 years; range: 42–56 years) who had a history of
ILD (Table 1). The study population also included 5 patients
who referred for an evaluation in a cardiac study. None of
the subjects had a history of suspected or documented
lung abnormalities.
Nine patients showed severe activity on the 99mTc-MIBI
scan, 4 patients had moderate uptake, and 6 patients had mild
activity (Figures 1 and 2). In the qualitative analysis, the
99mTc-MIBI scans in the 5 control patients showed no signifi-
cant uptake in the lungs (Figure 3).
All 19 ILD patients demonstrated a strong increase in
99mTc-MIBI uptake in the lungs compared to the control group
(Table 1). Scores for the 99mTc-MIBI scans were higher in the
patient group in both the early phase (0.24[0.19–0.31] vs
0.11[0.10–0.15], P< 0.05) and the delayed phase
(0.15[0.09–0.27] vs 0.04[0.01–0.09], P< 0.05) compared with
the control group. A positive correlation was detected between
the 99mTc-MIBI scans and the HRCT scores (Spearman’s
correlation coefficient¼ 0.65, P< 0.02) in the early phase
but not in the delayed phase in the patients (P> 0.14).
PFT grading of 7 patients were in grade 1 (normal); 3 were
in grade 2 (mild); 3 were in grade 3 (moderate); and 6 were
in grade 4 (severe). 99mTc-MIBI scan scores were not
significantly correlated with PFT findings and also age
(P value> 0.05).
The association among 99mTc-MIBI scans with HRCT
patterns including ground glass opacity, reticular fibrosis, and
99mTc-MIBI Scintigraphy in ILDhoneycombing was not significant (P> 0.05). Additionally, we
did not observe a significant association between 99mTc-MIBI
scan scores and HRCT scores in 3 classified zones (P> 0.05).
tween Patients and Control Groups in Different Lung Regions
P valuey Delayed Phase P Valuey
Case 0.13(0.06–0.22)
0.04 0.01
Control 0.04(0.01–0.07)
Case 0.17(0.08–0.35)
0.01 0.02
Control 0.07(0.01–0.09)
Case 0.19(0.10–0.35)
0.004 0.02
Control 0.10(0.01–0.13)
Case 0.14(0.06–0.20)
0.01 0.003
Control 0.02(0.04–0.07)
Case 0.15(0.06–0.27)
0.01 0.01
Control 0.01(0.04–0.09)
Case 0.18(0.09–0.29)
0.004 0.02
Control 0.06(0.01–0.12)
Case 0.15(0.09–0.27)
0.007 0.01
Control 0.04(0.01–0.09)
itrile.
www.md-journal.com | 3
FIGURE 1. (A) There was significant activity in the lung fields in the early views (left column) of 99mTc-MIBI scintigraphy of a 56-year-old
man, which persisted over the course delayed views up to 4h (right column). The early MIBI score was 0.25 and the delayed MIBI score
was 0.12. (B) HRCT scan of the same patient (score 14). HRCT¼high-resolution computed tomography, 99mTc-MIBI¼99mTc-methoxy-
isobutyl-isonitrile.
FIGURE 2. (A) There was significant activity in the lung fields in the early views (left column) of 99mTc-MIBI scintigraphy of a 54-year-old
man, which persisted over the course delayed views up to 4h (right column). The early MIBI score was 0.39 and the delayed MIBI score
was 0.35. (B) HRCT scan of the same patient (score 23). HRCT¼high-resolution computed tomography, 99mTc-MIBI¼99mTc-methoxy-
isobutyl-isonitrile.
Bahtouee et al Medicine  Volume 94, Number 47, November 2015
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Medicine  Volume 94, Number 47, November 2015 99mTc-MIBI Scintigraphy in ILDFive patients died and 14 patients were still alive over the
1-year follow-up period. Also, there was a significant difference
between the uptake intensity of 99mTc-MIBI and the outcome
in the early phase (dead: 0.32[0.29–0.43] vs alive: 0.21[0.18–
0.24], P< 0.05) and the delayed phase (dead: 0.27[0.22–0.28]
vs alive: 0.10[0.07–0.19], P< 0.05) (Table 2).
The washout rate (WR) was40 min starting from 20 min
up to 60 min and demonstrated a significant difference in our 2
FIGURE 3. There is no remarkable uptake on the early views (left co
The early MIBI score was 0.11 and the delayed MIBI score was 0.study groups (ILD: 46.61[15.61–50.39] vs NL: 70.91[27.09–
116.36], P¼ 0.04). The WR was acquired as follows: (early
MIBI score – delayed MIBI score)/early MIBI score  100.
DISCUSSION
The most important finding of this study underscores the
advantages of 99mTc-MIBI scintigraphy as a rapid and precise
imaging tool for the assessment of the inflammatory process in
the lungs. Although there was a total association between
99mTc-MIBI scintigraphy and HRCT scores, there were few
patients with higher 99mTc-MIBI scores in a lower HRCT
group compared to a higher HRCT group. This might imply
that anatomical imaging modalities are often improper for the
early detection of inflammation due to the consideration of
onlymorphological changes.22,23 However, a nuclear modality
can easily distinguish an inflammatory process because it is
based on functional processes that are morphologically indis-
tinguishable.24
In nuclear medicine fields, some radiopharmaceuticals
have been proposed for the detection of active interstitial
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.pulmonary lesions. For example, 67Ga-citrate is used in the
assessment of sarcoidosis and lung infections. A high uptake of
67Ga-citrate in the lung is reported in patients with severe
pulmonary fibrosis and dyspnea; however, it is not correlated
with the laboratory indices of the disease.12 Scintigraphy with
99mTc-DTPA aerosol is also a helpful modality in the study of
pulmonary epithelial permeability in patients with connective
tissue disease (CTD). In a recent study in patients with mixed
CTD, there was a diminished clearance time of 99mTc–DTPA,
which was improved after therapy.25 On the other hand, Anto-
niou et al26 reported that, in patients with idiopathic pulmonary
fibrosis, 99mTc-DTPA scintigraphy findings are not related to
HRCT and PFTs. Furthermore, an increased uptake was noted
in 111In–octreotide lung scans of patients with idiopathic
pulmonary fibrosis. Thus, the usefulness of radiopharmaceuti-
cals in the detection and evaluation of the severity of pulmonary
involvement in CTD is not yet established.4
The use of 99mTc-MIBI scanning is now widely used for
myocardial imaging. Additionally, it appears to have a role in
the diagnosis and staging of tumors, and in the noninvasive
assessment of ischemia in patients with peripheral vascular
diseases.27 Results from the present study indicate that the lung
uptake of 99mTc-MIBI was well-correlated with markedly
abnormal in patients with ILD who had clinical and/or radi-
ologic evidence of pulmonary involvement.
Several 99mTc-MIBI uptake mechanisms are thought to
n) and delayed views of 99mTc-MIBI scintigraphy (right column).
99mTc-MIBI¼99mTc-methoxy-isobutyl-isonitrile.contribute to its accumulation in the lung.14,28 On one hand, it is
thought to be due to an increased vascularity and vascular
permeability at the site of inflammation, and being lung
www.md-journal.com | 5
TABLE 2. The Comparison of 99mTc-MIBI Scintigraphy and HRCT Scores Between Living Patients and Those Who Died During
the Follow-Up Period
HIG Scintigraphy Score Outcome Early Phase P Value Delayed Phase P Value
Upper right lung E 0.34 (0.20–0.42) E 0.21 (0.16–0.28)
0.002 0.02
A 0.16 (0.12–0.19) A 0.10 (0.02–0.15)
Middle right lung E 0.40 (0.30–0.51) E 0.35 (0.28–0.36)
0.008 0.006
A 0.25 (0.19–0.29) A 0.13 (0.05–0.25)
Lower right lung E 0.44 (0.32–0.55) E 0.30 (0.27–0.36)
0.02 0.04
A 0.29 (0.25–0.38) A 0.14 (0.07–0.29)
Upper left lung E 0.24 (0.20–0.28) E 0.15 (0.12–0.24)
0.01 0.15

A 0.14 (0.10–0.19) A 0.10 (0.06–0.18)
Middle left lung E 0.31 (0.28–0.38) E 0.26 (0.18–0.29)
0.005 0.09

A 0.19 (0.15–0.23) A 0.08 (0.04–0.24)
Lower left lung E 0.38 (0.30–0.45) E 0.24 (0.21–0.29)
0.002 0.25

A 0.26 (0.19–0.28) A 0.13 (0.07–0.27)
Total lung E 0.32 (0.29–0.43) E 0.27 (0.22–0.28)
0.002 0.02
A 0.21 (0.18–0.24) A 0.10 (0.07–0.19)
HRCT score E 24.0 (17.75–34.0) 0.03
A 14.50 (10.75–21.25)
Just 3 regions were nonsignificant. All remaining parts were significant. A¼ alive, E¼ expire, HRCT¼ high-resolution computed tomography,
Bahtouee et al Medicine  Volume 94, Number 47, November 2015fibroblasts, pulmonary vascular endothelial cells, or inflamma-
tory cells infiltrating the parenchymal interstitium.29 On the
other hand, it could go back to the chemical characteristics of
radiopharmaceuticals, the cationic charge, the lipophilic proper-
ties, and the negative transmembrane potentials generated in the
cytoplasm and mitochondria of metabolically active cells.30
The lung uptake in patients who underwent a myocardial
perfusion imaging with suspected or confirmed cardiac disease
correlate well with the degree and severity of left ventricular
systolic dysfunction and angiographic coronary artery dis-
ease.16 In the absence of cardiac disease, as with our patient
group, these appearances may imply the presence of underlying
pulmonary processes. Furthermore, some of these causes may
include chronic smoking,31 chemical pneumonitis,32 atypical
pneumonias (P. carinii, MAC), lymphocytic interstitial pneu-
monia (LIP), and interstitial pneumonitis secondary to CTD,29
all of which were ruled out in our study. In the absence of these
situations, the radiotracer uptake in the lungs may most likely
represent ILD. However, sole radiotracer uptake in the diag-
nosis of ILD is nonspecific; thus, a tissue biopsy and histologic
examination are reasonable to verify the ILD diagnosis.
In the current investigation, there was no association
between 99mTc-MIBI scores and PFT results, which may
indicate the significance of 99mTc-MIBI scintigraphy in the
assessment of the severity of pulmonary involvement.
Alternatively, it is reported that 111In-octreotide uptake in
the lungs is correlated with the fibrosis score in HRCT, but not
99mTc-MIBI¼ 99mTc-methoxy-isobutyl-isonitrile.
Nonsignificant.with the ground-glass score in the idiopathic pulmonary fibrosis
patients.4 In contrast, there was no association between the
patterns HRCT and MIBI scores in the present study, which
6 | www.md-journal.commay be due to the different population and low numbers of
included cases in our study.
We also demonstrated the value of 99mTc-MIBI pulmon-
ary scintigraphy in its ability to differentiate active from
inactive pulmonary tuberculosis in 19 patients with history
of pulmonary tuberculosis.33
Likewise, Richard et al performed a pilot study to assess
the clinical significance of abnormal lung uptake of 99mTc-
MIBI in 16 patients with systemic sclerosis. The intensity of
uptake in the lungs was correlated with the extent of maximal
skin induration and with radiologic evidence of ILD, but not
with other clinical or laboratory factors of disease activity or the
extent of pulmonary involvement.19
What’s more, the 99mTc-MIBI scores in the present study
were significantly different in patients who were still living
compared to those who had died during the follow-up period,
which may represent promising results for the differentiation of
active and inactive lesions in future human studies. In terms of a
prognosis role for 99mTc-MIBI scans, few studies in patients
with lung cancer have been reported, and these have concluded
that 99mTc-MIBI scans can predict the survival of lung cancer
patients.34 However, due to small endpoints in our prospective
noncancer investigation, further larger and well-designed stu-
dies are necessary.
We depicted a lesser washout rate in ILD patients com-
pared with the healthy group (P< 0.05). This means that
99mTc-sestamibi elimination rates in ILD patients from 20
min to 60 min were less than the normal rates. In line with this,
Ruparelia et al reported pulmonary elimination rates of inhaled
99mTc-sestamibi radioaerosol in 26 in healthy smokers and 15
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
nonsmokers plus 7 patients with COPD (all ex-smokers) and 3
with ILD (all nonsmokers).35 The 99mTc-sestamibi elimination
rates in the ILD patients ranged from 6 to 30 min, were not
accelerated, and were 0.23, 0.32, and 0.35%min1.35 However,
the type of usage and washout period times were different
compared with our investigation times.
We also worked on 99mTc-IgG lung scintigraphy in the
assessment of pulmonary involvement in ILD in 8 patients
with ILD and 6 control participants.36 All 8 ILD patients
showed a strong increase in 99mTc-IgG uptake in the lungs
compared to the control patients. In the ILD patients, a
statistically significant positive correlationwas detected between
99mTc–IgG scans and HRCT scores (Spearman’s correlation
coefficient¼ 0.92, P< 0.008). Most findings in a recent study
with 99mTc-MIBI are similar to the 99mTc-IgG study.36
In the comparison of both radiopharmaceuticals (99mTc-
MIBI vs 99mTc-IgG) in the detection of pulmonary involve-
ment in ILD groups, we should point out that 99mTc-MIBI is
widely available and less expensive with a better quality
compared with 99mTc-IgG.
In the present study, we found differences between the
MIBI indices of the patient and control groups in the early and
delayed 99mTc-MIBI scans. Therefore, it seems that the 20-min
scan is sufficient and the delayed scintigraphy is not necessary.
In terms of radiation burden, typical effective radiation
dose from chest CT scan is 8.00 mSv and from 370 MBq (10
mCi) 99mTc-MIBI is 3.3 mSv.37,38 It is essential to note that
these are only typical values. Radiation doses vary for each
person due to differences in x-ray machines and their settings,
the amount of radionuclide given in nuclear medicine tech-
niques, and the patient’s metabolism.38
In summary, both 99mTc-MIBI and HRCT scans are
worthwhile in the assessment of the activity of pulmonary
involvement in ILD, particularly when the therapeutic response
is not satisfactory. These scans help in the decision for early
treatment to lessen patient morbidity and mortality as well as in
the prevention of disease aggravation.
Although our study revealed good insight into using
99mTc-MIBI as compared with clinical and radiological assess-
ments, it should be mentioned that it has some limitations. The
main limitations of this study were the small sample size and the
absence of lung biopsies in the participants as a gold standard
test, both of which may have influenced the results of this study.
Nevertheless, we did consider a mixed clinical presentation,
radiological modalities, and follow-up evaluation to alleviate
this deficiency. Our results should be corroborated in a larger
and well-designed study.
CONCLUSIONS
The present study demonstrated that a 99mTc-MIBI lung
scan might distinguish the severity of pulmonary involvement
in early views, which correlated well with the HRCT findings.
These results also revealed that 99mTc-MIBI lung scans might
be used as a complement to other diagnostic and clinical
examinations in terms of functional information in ILD. How-
ever, further investigations are strongly required.
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